Genitourinary Syndrome of Menopause – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of GSM for each country as well as annualized case counts projected to the national population.

We forecast the epidemiology of GSM patient populations in the major mature pharmaceutical markets covered in this report over 20 years.

Clarivate Epidemiology’s GSM forecast will answer the following question:

  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of GSM over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as a part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following GSM subpopulation:

  • Concurrent symptoms.

Note: Coverage may vary by country.

launch Related Market Assessment Reports